STAT reports that drug companies are seeking ways to shield their US sales from the effects of the Trump administration’s ‘most-favored nations’ policy. The policy aims to align US drug prices with those in other developed countries, prompting firms to reconsider how and where they introduce new medicines abroad.
This shift could delay or alter drug launches outside the US, affecting market access and patient availability in Europe and elsewhere. Pharma leaders need to track these policy changes closely, as they may influence revenue forecasts and regulatory strategies for international markets.
